- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Stocks in Play: Medicenna Therapeutics Corp. | 1 | Baystreet.ca | ||
| MEDICENNA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 09.04. | Medicenna Therapeutics Corp: Medicenna appoints Ibrahim as chief medical officer | 3 | Stockwatch | ||
| 18.03. | Medicenna Therapeutics Corp.: Medicenna to Present Preclinical Data from its First-in-Class Tumor Anchored and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the AACR Annual Meeting 2026 | 1 | GlobeNewswire (USA) | ||
| 13.02. | Medicenna Therapeutics Corp: Medicenna's Dec. 31 cash at $10.6 million | 1 | Stockwatch | ||
| 13.02. | Medicenna Therapeutics Corp: Medicenna appoints Sutin, Georgakis as directors | 1 | Stockwatch | ||
| 13.02. | Medicenna Therapeutics Corp.: Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results and Provides a Corporate Update | 1.468 | GlobeNewswire (Europe) | Medicenna to present updated internal and external data sets related to bizaxofusp (MDNA55) at the 7th Annual Glioblastoma Development Summit to be held in Boston from 17-19 February 2026 Updated... ► Artikel lesen | |
| 13.02. | Medicenna Therapeutics Corp.: Medicenna Announces Changes to Board Composition | 1.303 | GlobeNewswire (Europe) | TORONTO and HOUSTON, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the... ► Artikel lesen | |
| 15.01. | Medicenna Therapeutics Corp: Medicenna sets out plans, milestones for 2026 | 1 | Stockwatch | ||
| 15.01. | Medicenna Therapeutics Corp.: Medicenna Therapeutics Announces Key Program Updates and 2026 Outlook | 1.017 | GlobeNewswire (Europe) | Among monotherapy expansion cohorts (n=21), ORR was 50% in patients treated with MDNA11 in 2L/3L setting and 42% when MDNA11 was the next treatment post-ICI failure, showing best-in-class potential... ► Artikel lesen | |
| 10.12.25 | Medicenna Therapeutics Corp.: Medicenna Updates MDNA11 Clinical Trial Results at the ESMO-IO Congress 2025, Further Bolstering its Anti-Tumor Activity in Advanced Solid Tumors | 185 | GlobeNewswire (Europe) | MDNA11 demonstrates durable anti-tumor activity in phase-2 eligible expansion cohorts, enriched for immune checkpoint resistant melanoma, MSS endometrial cancer, MSI-H and TMB-H cancers, in each case... ► Artikel lesen | |
| 13.11.25 | Medicenna Therapeutics GAAP EPS of -C$0.06 | 1 | Seeking Alpha | ||
| 06.11.25 | Medicenna Therapeutics Corp: Medicenna joins Fondazione Melanoma for MDNA11 trial | 1 | Stockwatch | ||
| 06.11.25 | Stocks in Play: Medicenna Therapeutics Corp. | - | Baystreet.ca | ||
| 23.10.25 | Medicenna Therapeutics Corp.: Updated MDNA11 Clinical Data from the ABILITY-1 Study to be Presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2025 | 310 | GlobeNewswire (Europe) | TORONTO and HOUSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the... ► Artikel lesen | |
| 25.09.25 | Medicenna Therapeutics Corp.: Medicenna Announces Results of Annual Meeting of Shareholders | 146 | GlobeNewswire (Europe) | TORONTO and HOUSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the... ► Artikel lesen | |
| 01.08.25 | Medicenna Therapeutics Corp.: Medicenna Therapeutics Reports First Quarter Fiscal 2026 Financial Results and Operational Highlights | 220 | GlobeNewswire (Europe) | Updated cash guidance provides runway into at least the middle of calendar 2026 Company remains encouraged by MDNA11 clinical results presented to-date, demonstrating best-in-class potential of our... ► Artikel lesen | |
| 26.06.25 | Medicenna Therapeutics Corp.: Medicenna Therapeutics Reports Fiscal Year 2025 Financial Results and Operational Highlights | 412 | GlobeNewswire (Europe) | Updated cash guidance provides runway into at least mid-2026 MDNA11 Phase 1/2 clinical trial on track for data readouts in second half of the year as a single agent and in combination with KEYTRUDA®... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ADMA BIOLOGICS | 11,010 | +2,42 % | Does ADMA Biologics' Growth Story Outweigh Short-Seller Concerns? | ||
| KAILERA THERAPEUTICS | 26,010 | 0,00 % | Heißes Adipositas-IPO: Kailera will es mit den Großen aufnehmen | Der wachstumsstarke Markt für Appetitzügler ist heiß umkämpft. Immer mehr Player streben in den Markt, um sich mittel- bis langfristig ein Stück vom milliardenschweren Kuchen abzuschneiden. Auch Kailera... ► Artikel lesen | |
| ALAMAR BIOSCIENCES | 22,460 | 0,00 % | Alamar Biosciences Prices Upsized IPO At $17/shr; Raises $191.3 Mln | WASHINGTON (dpa-AFX) - Alamar Biosciences, Inc. Common Stock (ALMR) on Friday announced the pricing of its upsized initial public offering of 11.25 million shares of stock at $17 per share.The... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 342,50 | +6,72 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor | FDA assigned PDUFA target action date of January 29, 2027 No advisory committee meeting expected BOSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully... ► Artikel lesen | |
| QIAGEN | 35,350 | +1,00 % | BARCLAYS stuft QIAGEN NV auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Qiagen von 58 auf 44 Dollar gesenkt, aber die Aktie von "Overweight" auf "Equal Weight" abgestuft. Eine Übernahme... ► Artikel lesen | |
| COGENT BIOSCIENCES | 37,250 | +2,93 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026 | ||
| TREVI THERAPEUTICS | 15,210 | +4,61 % | Netflix, Trevi Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session | ||
| BIONTECH | 87,55 | +0,11 % | BioNTech-Wirkstoff BNT323 zeigt Wirkung bei Gebärmutterkrebs | BioNTech hat positive Daten aus einer Phase-2-Studie mit dem Antikörper-Wirkstoff-Konjugat Trastuzumab Pamirtecan (BNT323/DB-1303) veröffentlicht. In einer Kohorte mit stark vorbehandelten Patientinnen... ► Artikel lesen | |
| CG ONCOLOGY | 73,44 | +10,67 % | CG Oncology-Aktie erreicht Rekordhoch von 72,29 US-Dollar | ||
| SUMMIT THERAPEUTICS | 25,140 | +2,95 % | UBS reiterates Buy on Summit Therapeutics stock ahead of trial data | ||
| EVOTEC | 5,640 | +1,26 % | Aktien KW 15 Trump hält die Börsen im Griff. Wacklige Waffenruhe bringt Erholung, aber… News. Mutares. Evotec. TKMS. technotrans. HENSOLDT. Renk. Circus. Albis Leasing. Rheinmetall | Aktien - Erholungsaufatmer nach Waffenstillstand. Mit apokalyptischen Drohungen malte Trump die "Steinzeit" für den Iran an die Wand. Unter Vermittlung Pakistans - auch Chinas? - gab es kurz vorher... ► Artikel lesen | |
| IMMUNOVANT | 29,300 | +7,13 % | Immunovant Inc.: Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) | Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with previous findingsPatients in the TED studies demonstrated... ► Artikel lesen | |
| CABALETTA BIO | 3,440 | -2,27 % | Cellares' Cell Shuttle used in first patient infusions of Cabaletta Bio CAR T therapy | ||
| ERASCA | 18,995 | +4,20 % | Jefferies reiterates Erasca stock Buy rating on rival trial data | ||
| MOONLAKE IMMUNOTHERAPEUTICS | 18,340 | +3,06 % | H.C. Wainwright reiterates Moonlake stock rating on HS potential |
MEDICENNA THERAPEUTICS CORP gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MEDICENNA THERAPEUTICS CORP finden Sie auf Wallstreet Online.